- Home
- IMC vs FTH Comparison
IMC vs FTH Comparison
Compare IMC & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.72
N/A
Current Price
$18.33
Company Overview
Basic Information| Metric | IMC | FTH |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 728.3M | 835.7M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMC | FTH |
|---|---|---|
| Price | $10.72 | $18.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $55.38 |
| AVG Volume (30 Days) | 106.8K | ★ 345.2K |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.80 | $16.57 |
| 52 Week High | $12.00 | $42.14 |
Technical Indicators
Market Signals| Indicator | IMC | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 33.59 |
| Support Level | $6.23 | N/A |
| Resistance Level | $11.84 | $21.97 |
| Average True Range (ATR) | 1.16 | 2.11 |
| MACD | 0.48 | 0.14 |
| Stochastic Oscillator | 73.33 | 22.99 |
Price Performance
Historical Comparison IMC
FTH
About IMC IMC Rare Earths Ltd Ordinary Shares
IMC Rare Earths Ltd is a mineral exploration and development company engaged in the exploration, evaluation and development of minerals and metals in Brazil. Its main REE project is the Itarantim Project located in the States of Bahia and Minas Gerais, Brazil.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.